Russia has authorized the use of Sputnik Light, the single dose vaccine against CoViD-19. Sputnik Light is actually the first component of the Sputnik V vaccine, developed and released by Russia, earlier. This first component contained in Sputnik Light is the Recombinant Human Adenovirus Serotype Number 26 (rAd26). Sputnik Light is likely to be registered in several countries by as early as next week.
The advantage of Sputnik Light is that it can be used as a booster dose for other vaccines. The only thing is that the booster shot should undergo additional trials before administration, as per Kirill Dmitriev, CEO of Russian Direct Investment Fund. As it is a single dose vaccine, it can help to increase the rate of vaccinations in the face of the current resurge of CoViD-19 caused by new strains of SARS-CoV-2. The price is also less than $10.
In clinical trials, Sputnik Light demonstrated 79.4% efficacy. The data collected from 28 days after the administration of the vaccine. The efficacy of Sputnik V was reported to be nearly 92%. Sputnik Light has already passed Phase I/II Safety and Immunogenicity Study Trials. The vaccine could elicit the development of antigen specific IgG antibodies in 96.9% of volunteers on the 28th day of immunization.
India has already granted Emergency Use Authorization for Sputnik V and the first consignment comprising 1.5 lakh doses has arrived on 1 May in Hyderabad. Now the vaccine samples are undergoing test clearance at Central Drugs Laboratory, Kasauli, Himachal Pradesh. Dr. Reddy’s Laboratories, the marketing partner for Sputnik V in the country, however hasn’t fixed a price for the vaccine scheduled to be rolling out shortly.